Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Such integrative approaches may lead to more personalized and effective treatment strategies for ovarian cancer
They require ongoing monitoring
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
Vegan Friendly
US$ 21.09
US$ 27.05
US$ 26.52
US$ 24.12
US$ 21.38
